Affy Sets Sights on Downstream Market to Offset GWA Studies 'Trough'

To make up for the "lumpiness" of the market for genome-wide association studies, Affy will focus on applications that are downstream from GWAS, particularly in validation and routine testing, according to President and CEO Kevin King, who also shed some light on Affy's recent decision to sell its Clinical Services Laboratory to Navigenics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.